Galapagos is planning to wind down its cell therapy business, completing a whiplash change that saw the biotech go from focusing on the modality to ditching it in six months. Belgium-based Galapagos ...

Mechelen, Belgium; October 21, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced its intention to wind down its cell therapy business ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. After months of back-and-forth announcements, ...

Shares in Galapagos NV dropped sharply after the Belgian biotech firm said it would wind down its cell-therapy operations, putting paid to plans to sell the business off after no viable offers were ...

AMSTERDAM, Oct 21 (Reuters) - Biotechnology firm Galapagos (GLPG.AS), opens new tab said on Tuesday it would wind down its cell therapy business after attempts to sell it were unsuccessful, affecting ...

Galapagos (NASDAQ:GLPG) ADRs dropped ~13% in the premarket on Tuesday after the Belgian biotech announced plans to wind down its cell therapy business, impacting roughly 365 employees in Europe, the U ...

Following a disappointing performance from the company’s CAR-T candidate in an early-stage cancer trial, BioNTech is winding down cell therapy manufacturing at its inaugural U.S. plant. BioNTech will ...